Freiburg, Germany
Eleva, a pioneering biopharmaceutical firm headquartered in Germany, is committed to transforming the landscape of medicine through its innovative, moss-based technology. Founded in 1999, Eleva is on the cutting edge of biotechnology, focusing on the discovery and development of previously inaccessible biological therapeutics.
Their flagship clinical-stage program, Factor H (CPV-104), promises to unlock new therapeutic possibilities for patients with severe kidney disorders, dry AMD, and other complement-driven diseases. By targeting precision complement modulation, Eleva is set to redefine treatment paradigms in these areas.
The company’s last investment was a significant €60.00M venture round on 06 January 2021, led by Zukunftsfonds Heilbronn. This positions Eleva strongly for continued growth and expansion of its already promising drug pipeline.
